Population-based screening is eff ective in reducing the burden of colorectal cancer, and organised screening programmes have been implemented in many European countries. 1 Maximum participation in screening is crucial to achieve the greatest health benefi ts at population level. As with most cancer screening programmes, however, there is a gradient in uptake of colorectal cancer screening by socioeconomic status, from the most to the least deprived. [2] [3] [4] Because colorectal cancer screening results in earlier diagnosis or primary prevention, inequalities in colorectal cancer outcomes between socioeconomic groups are expected to increase with wider implementation of screening programmes. 5 The data on inequality in colorectal cancer screening are predominantly from the USA. 4 For Europe, analyses from the UK National Health Service Bowel Cancer Screening Programme, in which faecal occult blood testing is off ered to individuals aged 60-74 years at no cost, have shown uptake of 35% in the lowest socioeconomic quintile compared with more than 60% in the highest quintile. 3 In The Lancet, Jane Wardle and colleagues 6 present the results of the ASCEND project, which involved various mailed interventions aimed at lessening socioeconomic inequality for participation in the Bowel Cancer Screening Programme in England. Wardle and colleagues did four cluster-randomised controlled trials in which eligible individuals received either standard information about the screening programme or supplemented information in diff erent forms-a leafl et re-presenting the information in important to have adequate numbers of well trained and supervised staff with access to essential therapies and investigations; guidelines cannot compensate for weak health systems. Addressing issues in quality of care and supporting health systems is necessary to tackle the challenges of paediatric care in resource-limited settings in the era of the Sustainable Development Goals.
The WHO Hospital Care for Children guidelines, which includes the ETAT guidelines, are available in print 8 in many languages and in a new app (iOS and Android) that can be updated as new evidence becomes available and guidelines change.
14 There is, of course, still a need for simple guidelines for common conditions. The historical principles of WHO guidelines that are fi t for context and based on the best available evidence, using where possible the minimum number of highly predictive clinical signs or laboratory tests, all remain relevant. The new ETAT guidelines will need to be evaluated, and the design of such research should refl ect the broader context and recognise that these are not isolated simple interventions. Neither leafl et was associated with any eff ect on socioeconomic gradient of uptake of screening or on overall uptake. The endorsement letter did not aff ect the socioeconomic gradient but was associated with increased overall uptake (adjusted odds ratio [OR] 1·07, 95% CI 1·04-1·10). The enhanced reminder letter showed a signifi cant interaction with socioeconomic status gradient (p=0·005), with a stronger, albeit small, eff ect in the most deprived quintile (adjusted OR 1·11, 95% CI 1·04-1·20) than in the least deprived (1·00, 0·94-1·06), and overall uptake was also increased (1·07, 1·03-1·11). Regrettably, therefore, the laudable eff orts to make the screening invitation more understandable for people from lower socioeconomic groups had little eff ect, despite earlier evidence supporting general practice endorsement reminder enhancement. 7 Where to go from here is unclear. The study illustrates the challenges of reducing inequalities in screening uptake through written strategies alone, even when based on theory and practice. Thus, a uniform mailed screening invitation inevitably implies unequal chances of optimum colorectal cancer screening outcomes. This issue needs consideration because the aim of a population-based colorectal cancer screening programme is beyond equal participation. Rather, it is to off er an equal chance of optimum colorectal cancer outcomes to everyone.
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Providing equitable preventive care implies the use of equal screening invitation strategies in situations of equal information needs (horizontal equity). 8 However, that screening invitation strategy might need to diff er between subpopulations to achieve equal chances of optimum outcomes (vertical equity) is also implied. 8 This theory suggests that diff erent invitation strategies would be needed to provide people from all socioeconomic groups with equal chances of benefi ting from the screening off er. The only alternative option is to accept socioeconomic inequality in colorectal cancer screening. Strategies to increase awareness of the importance of screening in local communities, for example via general practitioners or telephone support in a variety of languages, might be options worth considering.
The second issue that needs to be addressed is related to the factual aim of the screening invitation. Colorectal cancer screening has potential side-eff ects, including potential harm, associated with follow-up colonoscopy. The importance of disclosing appropriate information to enable target groups to make informed decisions about participation has been emphasised. 9 Achieving this goal, however, is challenging because of the complexity of cancer screening programmes. 1 Wardle and colleagues 6 did not assess the decision-making process, although it seems unlikely that the small eff ect associated with the enhanced reminder strategy represents an increase in informed participation. That informed non-participation could explain the lack of increased participation in the trials of additional information leafl ets seems equally unlikely. Nevertheless, if the generally lower participation among groups with low socioeconomic status was proved to be based on informed autonomous choices to not participate, attempts to reduce the socioeconomic uptake gradient might be undesirable or even immoral. The question at stake is how to promote informed decision making about cancer screening participation eff ectively, especially in groups with low socioeconomic status. Isavuconazole: a role for the newest broad-spectrum triazole
Invasive mould infection is a serious complication of treatment for acute leukaemia and transplantation and is increasingly identifi ed with other underlying disorders. 1, 2 In The Lancet, Johan Maertens and colleagues 3 report a randomised, double-blind, non-inferiority study comparing a new broad-spectrum triazole, isavuconazole, with the current standard treatment, voriconazole, in 516 adult patients with suspected invasive mould infection. Isavuconazole was non-inferior to voriconazole by the primary endpoint of all-cause mortality at day 42 (19% [48 patients] in the isavuconazole group vs 20% [52 patients] in the voriconazole group) in an intentionto-treat population. The predefi ned 10% non-inferiority margin was met by an adjusted treatment diff erence in mortality of -1·0% (95% CI −7·8 to 5·7). Mortality is a more rigorous endpoint than overall response, which relies on interpretation of radiological fi ndings that might lag behind clinical improvement. 4 Fewer drugrelated adverse events were reported with isavuconazole (109 [42%] patients) than with voriconazole (155 [60%] patients), particularly those aff ecting eye, hepatobiliary system, and skin. 3 Will isavuconazole now replace voriconazole as standard of care for the treatment of invasive aspergillosis? Advantages of isavuconazole over voriconazole include its broader spectrum of activity (including most mucormycetes), once-daily dosing after the loading dose, linear pharmacokinetics, and less interpatient variability in exposure, water solubility (thus no need for cyclodextrin in the intravenous formulation), and fi nally fewer CYP enzyme-mediated drug-drug interactions. 5 Isavuconazole is cleared by, and is a moderate inhibitor of, CYP3A4. Exposure is not aff ected by CYP2C9 or CYP2C19 genotype or drug interactions. 5 This factor is an advantage, although clinicians have learnt to manage voriconazole sideeff ects, drug interactions, concentrations, and CYP2C19 genotypes in clinical practice. 6 Maertens and colleagues' study does have some limitations. Most patients were undergoing treatment for haematological malignant disease and none were receiving mould-active triazole prophylaxis. The eff ectiveness of isavuconazole treatment after mould-active triazole prophylaxis, a common practice in patients at risk for mould infection, remains to be clarifi ed. Further, few patients had mould infections other than aspergillosis, with more than 80% of mycologically documented infection in both groups being Aspergillus aff ecting the respiratory tract. 3 The eff ectiveness of isavuconazole against moulds other than aspergillus and infections involving sanctuary sites such as the eye and central nervous system requires further evaluation.
Although Maertens and colleagues 3 reported mean isavuconazole trough plasma concentrations at day 14 of 3354 ng/mL (SD 1816 ng/mL), similar to those in healthy volunteers, 5 experience in a more varied patient population, including those with gastrointestinal tract disturbances (eg, graft versus host disease, neutropenic enterocolitis, vomiting, diarrhoea, and nasogastric feeding), will be required to be certain that therapeutic drug monitoring is unnecessary. Although initial recommendations were that therapeutic drug
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